Factors predicting single-unit predominance after double umbilical cord blood transplantation

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Double umbilical cord blood transplantation (dUCBT), developed as a strategy to treat large number of patients with hematologic malignancies, frequently leads to the long-term establishment of a new hematopoietic system maintained by cells derived from a single umbilical cord blood unit. However, predicting which unit will predominate has remained elusive. This retrospective study examined the risk factor associated with unit predominance in 262 patients with hematologic malignancies who underwent dUCBT with subsequent hematopoietic recovery and complete chimerism between 2001 and 2009. Dual chimerism was detected at day 21-28, with subsequent single chimerism in 97% of the cases by day +100 and beyond. Risk factors included nucleated cell dose, CD34+ and CD3+ cell dose, colony-forming units-granulocyte macrophage dose, donor-recipient HLA match, sex and ABO match, order of infusion and cell viability. In the myeloablative setting, CD3+ cell dose was the only factor associated with unit predominance (odds ratio (OR) 4.4, 95% confidence interval (CI) 1.8-10.6; P<0.01), but in the non-myeloablative setting, CD3+ cell dose (OR 2.1, 95%CI 1.0-4.2; P=0.05) and HLA match (OR 3.4, 95%CI 1.0-11.4; P=0.05) were independent factors associated with unit predominance. Taken together, these findings suggest that immune reactivity has a role in unit predominance, and should be considered during graft selection and graft manipulation.

Original languageEnglish (US)
Pages (from-to)799-803
Number of pages5
JournalBone marrow transplantation
Issue number6
StatePublished - Jun 2012

Bibliographical note

Funding Information:
We thank Michael J Franklin (The University of Minnesota) for editing the manuscript. This work was supported in part by grants from the National Cancer Institute CA65493 (CGB, TED, BRB, JSM, PBM and JEW) and CA77598 (TED), Children’s Cancer Research Fund (JEW, TED and MRV), Universidad Católica de Chile (PR), American Cancer Society Audrey Meyer Mars International Fellowship in Clinical Oncology (PR), American Society of Blood and Marrow Transplantation Robert A. Good New Investigator Award (CGB), and the Leukemia and Lymphoma Society Scholar in Clinical Research Award (CGB).


  • double umbilical cord blood
  • myeloablative
  • nonmyeloablative
  • transplantation


Dive into the research topics of 'Factors predicting single-unit predominance after double umbilical cord blood transplantation'. Together they form a unique fingerprint.

Cite this